netFormulary NHS
Calderdale and Huddersfield
NHS Foundation Trust
 Formulary Chapter 2: Cardiovascular system - Full Section

02.01 Positive inotropic drugs
02.01.01 Cardiac glycosides
Digoxin-specific antibody
02.01.02 Phosphodiesterase type-3 inhibitors
02.02 Diuretics
02.02.01 Thiazides and related diuretics
02.02.02 Loop diuretics
02.02.03 Potassium-sparing diuretics and aldosterone antagonists
Aldosterone antagonists
02.02.04 Potassium-sparing diuretics with other diuretics
02.02.05 Osmotic diuretics
02.02.06 Mercurial diuretics
02.02.07 Carbonic anhydrase inhibitors
02.02.08 Diuretics with potassium
02.03 Anti-arrhythmic drugs
02.03.01 Management of arrhythmias
02.03.02 Drugs for arrhythmias
Supraventricular arrhythmias
Supraventricular and ventricular arrhythmias
Ventricular arrhythmias
02.04 Beta-adrenoceptor blocking drugs
02.05 Drugs affecting the renin-angiotensin system and some other antihypertensive drugs
02.05.01 Vasodilator antihypertensive drugs
02.05.02 Centrally acting antihypertensive drugs
02.05.03 Adrenergic neurone blocking drugs
02.05.04 Alpha-adrenoceptor blocking drugs
02.05.05 Drugs affecting the renin-angiotensin system
Heart Failure Angiotensin-converting enzyme inhibitors (ACE inhibitors) Angiotensin-II receptor antagonists Renin inhibitors
02.06 Nitrates, calcium-channel blockers, and potassium-channel activators
02.06.01 Nitrates
02.06.02 Calcium-channel blockers
02.06.03 Other anitanginal drugs
02.06.04 Peripheral vasodilators and related drugs
Other preparations used in peripheral vascular disease
02.07 Sympathomimetics
02.07.01 Inotropic sympathomimetics
02.07.02 Vasoconstrictor sympathomimetics
02.07.03 Cardiopulmonary resuscitation
02.08 Anticoagulants and protamine
02.08.01 Parenteral anticoagulants
Low molecular weight heparins
Heparin flushes
02.08.02 Oral anticoagulants
Stroke prevention in AF
VTE treatment
VTE prophylaxis in hip/knee surgery
02.08.03 Protamine sulphate
02.09 Antiplatelet drugs
02.10 Stable angina, acute coronary syndromes, and fibrinolysis
02.10.01 Management of stable angina and acute coronary syndromes
02.10.02 Fibrinolytic drugs
02.11 Antifibrinolytic drugs and haemostatics
Blood-related products
02.12 Lipid-regulating drugs
Bile acid sequestrants
Nicotinic acid group
Omega-3 fatty acid compounds
PCSK9 inhibitors
Other lipid modifying agents
02.13 Local sclerosants